Cerca
Close this search box.

Clinical rationale of using steerable technologies for radiofrequency ablation followed by cavity creation and cement augmentation in the treatment of painful spinal metastases

Data pubblicazione

2023/4/19

Editore

MDPI

Autori

Claudio Pusceddu, Salvatore Marsico, Daniele Derudas, Nicola Ballicu, Luca Melis, Stefano Zedda, Carlo De Felice, Alessandro Calabrese, Domiziana Santucci, Eliodoro Faiella

Abstract

(1) Background: Cement distribution after radiofrequency ablation of spinal metastases can be unpredictable due to various tumor factors, and vertebral augmentation requires advanced devices to prevent cement leakage and achieve satisfactory filling. The purpose of this study is to evaluate the safety and efficacy of a platform of steerable technologies with an articulating radiofrequency ablation (RFA) probe and targeted cavity creation before vertebral augmentation in the treatment of painful spinal metastases. (2) Methods: Sixteen patients (mean age, 67 years) underwent RFA in conjunction with vertebral augmentation after the creation of a targeted balloon cavity for metastatic spinal disease and were followed up to 6 months. Pain and functional mobility were assessed before treatment and postoperatively using the Visual Analogue Score (VAS) and Functional Mobility Scale (FMS). Complications, predictability of cement distribution, anatomical restoration, and local recurrence were collected. Technical success was defined as successful intraoperative ablation and predictable cement distribution after cavity creation without major complications. (3) Results: Sixteen patients with 21 lesions were treated for tumors involving the thoracolumbar spine. All treatments were technically successful and were followed by targeted cavity creation and vertebral augmentation. A statistically significant reduction in median VAS score was observed before treatment and 1 week after RFA treatment (p < 0.001). A total of six of the seven patients who reported limited painful ambulation before treatment reported normal ambulation 1 month after treatment, while …

Pagine

4257-4268

Contatti

Dott. Claudio Pusceddu – Mater Olbia Email: clapusceddu@gmail.com Telefono: 380 30 89 094